Perinatal tuberculosis in Australia: screening and prevention

Perinatal tuberculosis is uncommon in Australia, but missed disease can harm a pregnant person, fetus, newborn and family. It includes congenital infection acquired before birth and postnatal infection from an infectious adult. The concerns are vertical transmission from mother to fetus or newborn and close postnatal exposure. The key distinction is active TB, which may infect the baby, from latent TB infection, which can reactivate later. Each requires a distinct testing and treatment pathway.

An antenatal clinician should not label every cough as TB, yet must recognise persistent cough, fever, night sweats, weight loss, fatigue, abdominal or pelvic symptoms, or lymph-node enlargement. Pregnancy can disguise these signs as reflux, anaemia or viral illness. Exposure to a close contact, untreated latent infection, healthcare work without protection, travel or residence in a high-incidence setting, and household crowding justify investigation. History should guide care, not assumptions about nationality.

TB is not evenly distributed in Australia. Sydney, Melbourne, Brisbane, Perth and other cities contain communities with connections to places where TB remains common; international students, migrants and returned travellers may bring histories that are not obvious. Most respiratory symptoms do not indicate TB. The response is targeted screening and rapid referral when suspicion is high—not automatic testing for everyone, and never stigma that delays care.

Good prevention joins laboratory results, specialist prescribing, public-health tracing and a newborn plan. The FAOPS 2020 congress archive preserves the scientific programme for the 21st Federation of Asian and Oceania Perinatal Societies meeting in Tokyo, although the congress was cancelled in April 2020 because of COVID-19 and international travel difficulties. Its multidisciplinary focus remains relevant: perinatal care must withstand outbreaks and service pressure without losing follow-up.

Who needs assessment during pregnancy

Begin with a focused exposure history. Ask who lives at home, whether anyone has had TB, when treatment ended, and whether the patient received preventive therapy. Record previous TST or IGRA results, BCG vaccination, birth countries and recent travel. Ask healthcare workers about occupational exposure and access to respirators.

Pregnancy itself does not make TB more likely, but it can make disease harder to recognise. A pregnant person with compatible symptoms needs prompt review and a respiratory or infectious-diseases referral; severe breathing difficulty, haemoptysis or collapse requires emergency care. Ask about abdominal pain, genital lesions and pelvic symptoms because extrapulmonary sites can be mistaken for obstetric complications.

Risk factors should trigger a plan, not a label. People who are homeless, live in crowded accommodation, work in detention or congregate settings, or had close contact with infectious TB may need testing even without symptoms. Aboriginal and Torres Strait Islander families should receive respectful, clinically indicated assessment through appropriate services. Public-health units can help obtain exposure histories and arrange contact tracing.

Screening tests during pregnancy

IGRA blood tests and tuberculin skin tests screen for TB infection; they do not prove active disease. With prior BCG, IGRA is often preferred because BCG can cause a positive skin test. Results still require context from exposure, geography and immune status, and a negative result cannot exclude active TB with symptoms. Australian protocols, informed by WHO and ATS/CDC/IDSA principles, should guide testing.

An IGRA uses blood and does not expose the fetus to radiation. If active pulmonary TB is suspected, use sputum for microscopy, culture and molecular testing, with a chest radiograph when clinically indicated. Justify radiography rather than ordering it for every exposed asymptomatic person; an indicated examination carries a small fetal radiation dose and should be explained.

After birth, BCG can make an infant’s skin test positive, and neonatal immune responses complicate interpretation. Paediatric teams may use serial skin tests, IGRA, examinations, imaging and microbiology according to local guidance. Any infant with fever, respiratory distress, poor feeding, weight loss or lymph-node disease needs urgent assessment, even after a negative screening test, because congenital TB can present after the first week.

Choosing chemoprophylaxis for latent infection

Chemoprophylaxis, now often called TB preventive treatment, is used after active disease has been excluded. For latent infection during pregnancy, an infectious-diseases specialist may recommend daily isoniazid, usually with pyridoxine to reduce neuropathy risk. Rifamycin-based or shorter regimens have different pregnancy evidence, resistance considerations and interactions, so they should not be copied from internet advice or started without a clinician.

The decision weighs reactivation risk, recent exposure, age, immune status and ability to complete treatment. A close infant contact or pregnant person with substantial exposure may need window prophylaxis before repeat tests become positive, but only after active disease is assessed. With symptoms, obtain specimens and contact the TB service promptly; clinically significant infectious TB should not wait for a final culture result.

Monitoring includes medicines, liver risk and pregnancy complications, symptom checks and indicated blood tests. Isoniazid can interact with some antiretroviral, anticonvulsant and other medicines; pharmacists and the maternity team should review the full list. Breastfeeding is often possible with standard TB medicines, although infectious pulmonary disease requires separate infection-control advice. Directly observed therapy may support adherence when needed.

Outcome review should include maternal recovery, birth outcomes and child development alongside sputum results. Structured, multidisciplinary measurement is illustrated by neuropsychology in multiple sclerosis, which discusses how cognitive and functional assessment can reveal meaningful effects in chronic illness. That paper is not TB-specific, so its findings should not be transferred directly; the useful lesson is to agree on outcomes and review them over time.

Managing confirmed maternal TB

Confirmed or strongly suspected active TB in pregnancy requires urgent coordination between obstetric, infectious-diseases, respiratory, laboratory and public-health teams. Notify the relevant state or territory health authority, and contact tracing may identify others at risk. Treatment often uses several first-line medicines considered compatible with pregnancy, but resistance, side effects, gestational age and other conditions require specialist selection.

Delivery mode is based on obstetric need and disease status. Vaginal birth is not automatically excluded for a treated patient; caesarean section may be needed for genital lesions or another obstetric indication. Infectious pulmonary TB requires airborne precautions in hospital and advice about newborn contact. Infection-control teams should make a safe rooming-in and breastfeeding plan rather than apply a blanket separation rule.

The newborn needs a documented plan: examination, appropriate microbiological testing, chest imaging when indicated, consideration of preventive treatment after significant exposure, and reliable paediatric and public-health follow-up. BCG availability and indications differ across Australian states and territories; vaccination does not reliably block transmission and must not delay treatment of an exposed or ill infant.

Australian services, law and daily life

Australian families usually enter the system through a GP, midwife, obstetric clinic or public maternity service, with infectious-diseases and respiratory clinics providing specialist advice. Public-health units coordinate notifiable-disease responses, and interpreters should be available. Medicare subsidises many physician and hospital services, while pathology and imaging access depends on referral and local arrangements. In the Australian market, TB medicines are prescription products; active-disease treatment is commonly organised through specialist and public-health services rather than ordinary retail pharmacy purchasing.

Everyday circumstances affect exposure and access. Apartment towers in Sydney or Melbourne, shared transport, childcare centres and university residences make close contact common, but they do not make a neighbourhood unsafe. Staying home when unwell, covering coughs, improving ventilation and requesting a mask in healthcare are practical Australian habits. In regional areas, telehealth shortens the distance to specialist advice, while travel may interrupt treatment; planned supplies are better than an unplanned gap.

TB is notifiable in Australia, with the exact process set by state and territory public-health legislation. The Privacy Act 1988 and applicable state health-records laws shape how personal information is collected and shared. Mandatory notification does not mean automatic exclusion from work, school or childcare. Public-health teams can investigate transmission while keeping information confidential and proportionate, helping families cooperate without being blamed.

Structured data also improves care. Registries linking maternal diagnoses, medicines, birth outcomes and infant follow-up can reveal gaps a single visit misses; the international pregnancy registry illustrates coordinated pregnancy data. Local pathology and the treating clinician’s assessment remain the basis for individual decisions, while public-health records support safer follow-up and outbreak control.

A practical pathway for families and clinicians

A reliable pathway should fit a busy antenatal appointment and prevent missed handoffs. Families can use these prompts:

For pregnant people and families

  • Share recent TB exposure, previous diagnosis or treatment, BCG history, and relevant birth-country or travel history.
  • Request targeted testing when symptoms or exposure justify it; do not self-start isoniazid or other TB medicines.
  • Bring medication and allergy lists to specialist visits, and keep newborn appointments and public-health contact details together.

Clinicians and maternity services can use a parallel safety checklist:

For clinicians and maternity teams

  • Use IGRA or TST according to BCG status and risk, while investigating active disease separately when symptoms are present.
  • Obtain sputum, culture or molecular tests and indicated imaging, then interpret results with pregnancy and exposure context.
  • Document maternal treatment, drug susceptibility results, the infant examination and follow-up tests; involve the local TB service early.

The main pathways can be compared directly:

Situation Assessment Next step
Recent contact, no symptoms Exposure history; IGRA or TST TB-service assessment; preventive treatment if indicated
Pregnancy with symptoms Sputum tests; indicated imaging Urgent specialist referral; exclude active TB
Latent infection IGRA or TST plus clinical review Specialist preventive treatment and monitoring
Maternal infectious TB near birth Newborn examination and testing Infant preventive plan, notification and follow-up

Protecting infants and planning follow-up

After exposure or treatment, the infant’s clinical condition matters more than one screening result. A well baby may still need preventive treatment, serial reviews and prompt investigation if feeding or breathing changes. Congenital TB can appear later, so weight gain, temperature, respiratory effort, lymph nodes and general wellbeing belong in the follow-up plan.

Public-health advice should address return to childcare or school, household contacts and treatment adherence without unnecessary isolation. Longer-term review can include growth, development and hearing after serious illness, with paediatric referral if concerns arise. The maternity team, TB service, laboratory, general practitioner and child-health clinician should know the next appointment and who is responsible.

If there has been recent TB exposure, a household diagnosis or compatible symptoms during pregnancy, contact your GP, maternity clinician or local TB service promptly rather than waiting for a routine review. Ask for a documented pathway covering active-disease exclusion, preventive treatment, newborn assessment and follow-up. Early referral and coordinated action protect the mother, baby and wider Australian community.